JP2021523949A5 - - Google Patents
Info
- Publication number
- JP2021523949A5 JP2021523949A5 JP2021514466A JP2021514466A JP2021523949A5 JP 2021523949 A5 JP2021523949 A5 JP 2021523949A5 JP 2021514466 A JP2021514466 A JP 2021514466A JP 2021514466 A JP2021514466 A JP 2021514466A JP 2021523949 A5 JP2021523949 A5 JP 2021523949A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding moiety
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672602P | 2018-05-17 | 2018-05-17 | |
| US62/672,602 | 2018-05-17 | ||
| PCT/CN2019/087287 WO2019219064A1 (en) | 2018-05-17 | 2019-05-16 | Antibody binding pd-1 and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523949A JP2021523949A (ja) | 2021-09-09 |
| JP2021523949A5 true JP2021523949A5 (enExample) | 2022-05-26 |
| JP7535503B2 JP7535503B2 (ja) | 2024-08-16 |
Family
ID=68534222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514466A Active JP7535503B2 (ja) | 2018-05-17 | 2019-05-16 | Ｐｄ－１に結合する抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11136394B2 (enExample) |
| EP (1) | EP3794039A4 (enExample) |
| JP (1) | JP7535503B2 (enExample) |
| KR (1) | KR20210010998A (enExample) |
| CN (1) | CN112236455B (enExample) |
| WO (1) | WO2019219064A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048704A4 (en) | 2019-10-21 | 2023-11-22 | Nanjing Leads Biolabs Co., Ltd. | RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß |
| MA59827B1 (fr) | 2020-05-26 | 2024-10-31 | Boehringer Ingelheim International Gmbh | Anticorps anti-pd-1 |
| MX2023011663A (es) * | 2021-03-31 | 2023-10-11 | Merus Nv | Dominios de union a pd-1 novedosos. |
| WO2023011654A1 (zh) * | 2021-08-06 | 2023-02-09 | 启愈生物技术(上海)有限公司 | 抗pd-1纳米抗体及其应用 |
| CN120590537A (zh) * | 2021-12-31 | 2025-09-05 | 南京维立志博生物科技股份有限公司 | 靶向tigit的双特异性抗体 |
| CN118620082A (zh) * | 2023-03-10 | 2024-09-10 | 南京维立志博生物科技有限公司 | 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| MX388181B (es) * | 2014-07-22 | 2025-03-19 | Cb Therapeutics Inc | Anticuerpos anti-pd-1. |
| WO2016077397A2 (en) * | 2014-11-11 | 2016-05-19 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| EP4378957A3 (en) * | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CA3132021C (en) * | 2015-11-18 | 2024-03-12 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| US20210177896A1 (en) * | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
-
2019
- 2019-05-16 WO PCT/CN2019/087287 patent/WO2019219064A1/en not_active Ceased
- 2019-05-16 CN CN201980033192.7A patent/CN112236455B/zh active Active
- 2019-05-16 JP JP2021514466A patent/JP7535503B2/ja active Active
- 2019-05-16 KR KR1020207035530A patent/KR20210010998A/ko active Pending
- 2019-05-16 EP EP19804070.1A patent/EP3794039A4/en active Pending
- 2019-05-16 US US16/414,724 patent/US11136394B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7790754B2 (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| US12258411B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP6822849B2 (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| EP3222634A1 (en) | Antibodies to human programmed death receptor pd-1 | |
| JP2019500891A5 (enExample) | ||
| CN111094348B (zh) | 双特异性抗pd1-抗tim3抗体 | |
| KR20200123164A (ko) | Lag3 및 pd1에 결합하는 치료 분자 | |
| US20230114801A1 (en) | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | |
| US20250064909A1 (en) | Anti-tigit antibodies and use thereof | |
| US20200347137A1 (en) | Bispecific antibodies and methods of making and using thereof | |
| Luan et al. | A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity | |
| WO2021167885A1 (en) | Cd137 binding molecules and uses thereof | |
| AU2022253202A9 (en) | Gucy2c binding polypeptide and uses thereof | |
| US12391758B2 (en) | Anti-PD-L1 cancer immunotherapy antibodies | |
| EP4606384A1 (en) | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| US20230265185A1 (en) | Anti-cd22 single domain antibodies and therapeutic constructs | |
| CN111971303A (zh) | 抗cd27抗体及其用途 | |
| RU2808138C1 (ru) | Антитело, нацеливающееся на cd3, биспецифическое антитело и их применение | |
| HK40127540A (en) | Use of anti-cldn4-anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| KR20260035361A (ko) | 폴리오바이러스 수용체에 대한 항체 및 이의 용도 | |
| EA052933B1 (ru) | Применение биспецифического антитела против cldn4/против cd137 в комбинации с ингибитором сигнала pd-1 для лечения злокачественной опухоли | |
| JP2025087939A (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用 | |
| WO2023056354A1 (en) | Siglec receptor check point inhibitors and method of using them to inhibit neoplastic cell growth | |
| HK40112413A (zh) | 与PD-L1、CD137和/或TGFβ的双特异性和三特异性结合蛋白及其用途 |